Clinical Trials Browser

Phase 1 × Paclitaxel × 90 days × Clear all

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Terminated

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05819892 2026-05-20

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

Endometrial Neoplasms

NCT03279237 2026-05-18

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Phase 1 Completed

25 enrolled 9 charts

Gastrointestinal

GastroEsophageal Cancer

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Phase 1 Not yet recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06840886 2026-05-14

A Study of PHST001 in Advanced Solid Tumors

Phase 1 Recruiting

CNSGastrointestinalGynecologic

Ovarian Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05673200 2026-05-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms

NCT07580833 2026-05-12

A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors

Phase 1 Not yet recruiting

Breast Neoplasms

NCT03932409 2026-05-08

FIERCE

Phase 1 Active not recruiting

Endometrial Neoplasms

NCT05954312 2026-05-08

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Neoplasms

NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

NCT05365581 2026-05-05

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Phase 1 Recruiting

Adenocarcinoma

NCT03537690 2026-04-29

FID-007 in Treating Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT02379416 2026-04-21

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Phase 1 Completed

Neoplasms

NCT06964009 2026-04-21

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Phase 1 Recruiting

Ovarian Neoplasms

NCT01281176 2026-04-20

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

Adult Solid Neoplasm

NCT05307705 2026-04-20

PIKASSO-01

Phase 1 Active not recruiting

Breast Neoplasms

NCT06447662 2026-04-20

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06561685 2026-04-20

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Neoplasm Metastasis

NCT01187199 2026-04-16

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04615013 2026-04-16

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Phase 1 Recruiting

GastrointestinalGynecologic

Cervical Esophagus Adenocarcinoma

NCT04220827 2026-04-15

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Phase 1 Active not recruiting

Peritoneal Neoplasms

NCT05039801 2026-04-15

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1 Recruiting

DermatologicGynecologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT05142189 2026-04-14

LuCa-MERIT-1

Phase 1 Recruiting

EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT06333951 2026-04-13

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02390427 2026-04-09

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT04516447 2026-04-07

MUIR

Phase 1 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03798626 2026-04-01

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Phase 1 Completed

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms

NCT06110195 2026-03-31

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

Phase 1 Terminated

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04722523 2026-03-30

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05254184 2026-03-30

KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05017012 2026-03-27

MK-3475A-C18

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05768932 2026-03-27

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Recruiting

BreastGastrointestinalOther hematologic neoplasm

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT03044613 2026-03-23

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

Phase 1 Active not recruiting

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT07477743 2026-03-17

A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor Cancer

NCT01374620 2026-03-16

PAL-ANGI2

Phase 1 Completed

Neoplasms

NCT03725436 2026-03-16

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT06173349 2026-03-13

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Phase 1 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Phase 1 Recruiting

Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06883630 2026-03-05

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung